The incidence of non-small cell lung cancer (NSCLC) is the highest among malignant tumors. StagesⅡtoⅢA patients are potentially treatable. Perioperative chemotherapy is the standard treatment for NSCLC; however, in patients with the EGFR mutation, neoadjuvant or adjuvant targeted therapy can improve disease-free survival (DFS). Despite this, the survival benefit is not clear. Postop-erative adjuvant radiotherapy can enhance survival in patients with stageⅢA (N2) NSCLC. Durvalumab maintenance therapy, after concurrent chemoradiotherapy, has become the new standard for patients with locally advanced and unresectable NSCLC. Immuno-therapy requires additional investigation in patients with driver gene mutations, as does the combination of immunotherapy plus che-motherapy. Notably, anti-angiogenesis therapy has failed as a postoperative adjuvant therapy.